About John Tilton
Form D filings for Hemoshear Therapeutics from 2021 to 2023 list John Tilton as director.
John Tilton first appears on SEC filings in 2021.
Experience
This experience comes from SEC filings. The years are when the filings name John Tilton in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people John Tilton works with at each company, as listed on that company's latest Form D.
Hemoshear Therapeutics, Inc. · Form D, Nov 14, 2023
MI
Michael Innes
Executive officer
DF
David Friedman
Director
PH
Patrick Horn
Executive officer
BJ
Brian Johns
Executive officer
HI
H. Watkins III
Director
JI
John Brooks III
Director
KM
Kathleen Metters
Director
AH
Aric Holsinger
Chief Financial Officer
BW
Brian Warmhoff
Executive officer and director
RG
Robert Gould
Director